Gadobenate Dimeglumine
drugOn this page
Also known as Acide gadobeniqueAcido gadobenicoB-19036B-19036/7B19036/7B1903617GadobenateGadobenic acidGadobenic acid meglumineGadobenoate dimeglumineMeglumine gadobenateMultihanceMultihance multipackferucarbutran
Summary
Gadobenate Dimeglumine (CHEMBL1200571) is an approved small molecule (ATC V08CA08); indicated across 2 conditions including congenital heart disease and breast neoplasm.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: V08CA08
- Indications: 2 conditions
- Clinical trials: 21
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200571 |
| Name | Gadobenate Dimeglumine |
| Type | Small molecule |
| Max phase | 4 |
| ATC | V08CA08 |
Also known as: Acide gadobenique, Acido gadobenico, B-19036, B-19036/7, B19036/7, B1903617, Gadobenate, Gadobenate dimeglumine, Gadobenic acid, Gadobenic acid meglumine, Gadobenoate dimeglumine, Meglumine gadobenate
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| congenital heart disease | 3 | MONDO:0005453 | EFO:0005207 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
Clinical trials
Total trials: 21.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 6 |
| PHASE4 | 5 |
| Not specified | 5 |
| PHASE2 | 4 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04373564 | PHASE4 | RECRUITING | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years |
| NCT00323102 | PHASE4 | COMPLETED | A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain |
| NCT00395863 | PHASE4 | COMPLETED | Multihance at 3 Tesla (3T) in Brain Tumors |
| NCT02070380 | PHASE4 | COMPLETED | Crossover Comparison of MultiHance and Dotarem |
| NCT04973007 | PHASE4 | TERMINATED | Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases |
| NCT00323310 | PHASE3 | TERMINATED | Safety and Efficacy of MultiHance in Pediatric Patients |
| NCT00408083 | PHASE3 | COMPLETED | Crossover Study With MultiHance vs a Comparator for Peripheral MRA |
| NCT00415805 | PHASE3 | COMPLETED | Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent |
| NCT00486473 | PHASE3 | COMPLETED | Multihance Versus Magnevist in Breast MRI |
| NCT01260636 | PHASE3 | COMPLETED | Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries |
| NCT06406517 | PHASE3 | UNKNOWN | Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics |
| NCT01710254 | PHASE2 | COMPLETED | Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients |
| NCT02633501 | PHASE2 | COMPLETED | P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) |
| NCT03703492 | PHASE2 | COMPLETED | Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS |
| NCT04910425 | PHASE2 | WITHDRAWN | PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer |
| NCT00411931 | PHASE1 | COMPLETED | A Pharmacokinetics Study of MultiHance in Pediatric Patients |
| NCT02291822 | Not specified | COMPLETED | Retrospective Study of MRI in Pediatric Patients |
| NCT02967380 | Not specified | TERMINATED | Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases |
| NCT03091803 | Not specified | WITHDRAWN | QSM and Regional DCE MRI Permeability Using GOCART Technique |
| NCT03147989 | Not specified | COMPLETED | Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients |
| NCT04132843 | Not specified | COMPLETED | Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: congenital heart disease